What does this research mean for the field?

Super-sensitivity cardiac troponin assays detect troponin in nearly all healthy individuals and significantly improve risk prediction and reclassification for future cardiovascular events compared to lower-sensitivity assays. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

March 4, 2014Open Access

Comparison of Three Troponins as Predictors of Future Cardiovascular Events – Prospective Results from the FINRISK and BiomaCaRE Studies

Structured PICO

Does super-sensitivity troponin I measurement improve cardiovascular risk prediction compared to contemporary or high-sensitivity assays in a general population without prior CVD?

Population

7,899 participants of the general-population based FINRISK 1997 cohort without a history of cardiovascular disease (CVD) events

Intervention

Troponin I measurement using a super-sensitivity assay

Comparator

Contemporary-sensitivity and high-sensitivity troponin I assays

Outcome

Cardiovascular disease (CVD), myocardial infarction (MI), ischemic stroke, heart failure (HF), and major adverse cardiac events (MACE)hard clinical

Super-sensitivity troponin I assays improve cardiovascular risk prediction and reclassification in a healthy general population compared to less sensitive assays.

Abstract

IMPORTANCE AND OBJECTIVE: Besides their role in diagnosis of acute myocardial infarction (MI), troponins may be powerful biomarkers for risk stratification in the general population. The objective of our study was to compare the performance of three troponin assays in cardiovascular disease (CVD) risk prediction in a population-based cohort without a history of CVD events. DESIGN, SETTING AND PARTICIPANTS: Troponin I concentrations were measured using a contemporary-sensitivity, high-sensitivity, and super-sensitivity assay in 7,899 participants of the general-population based FINRISK 1997 cohort. We used Cox proportional hazards regression to determine relative risks, followed by measures of discrimination and reclassification using 10-fold cross-validation to control for over-optimism. MAIN OUTCOME: As outcome measures we used CVD, MI, ischemic stroke, heart failure (HF), and major adverse cardiac events (MACE). During the follow-up of 14 years 1,074 incident MACE were observed. RESULTS: Values above the lower limit of detection were observed in 26.4%, 81.5% and 93.9% for the contemporary-sensitivity, high-sensitivity and super-sensitivity assay, respectively. We observed significant associations of troponin concentrations with the risk of future CVD events and the results tended to become stronger with increasing assay sensitivity. For the super-sensitivity assay the multivariate adjusted hazard ratios (per one standard deviation increase) for different outcomes were: MI 1.24 95% CI 1.11-1.39, stroke 1.14 1.01-1.28, CVD 1.15 1.07-1.24, HF 1.28 1.18-1.39, and MACE 1.18 1.11-1.25. In subjects with intermediate risk, we found an improvement of net reclassification for HF (10.2%, p<0.001), and MACE (5.1%, p<0.001). CONCLUSION: Using a super-sensitivity assay, cardiac troponin was detectable in almost all healthy individuals. Its concentration improved risk prediction and reclassification for cardiovascular endpoints.

KI fragen

Bookmark

View Full Paper